HomeInsightsStock Comparison

Mankind Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Mankind Pharma Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 13, 2025

Key Highlights

  • The Latest Trading Price of Mankind Pharma Ltd is ₹ 2386 as of 12 Jun 15:30.
  • The P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 48.1 on March 2024 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 92029 crore on March 2024 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Mankind Pharma Ltd for the Mar '25 is ₹ 3333 crore as compare to the Dec '24 revenue of ₹ 3285 crore. This represent the growth of 1.43% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Mankind Pharma Ltd for the Mar '25 is ₹ 932.5 crore as compare to the Dec '24 ebitda of ₹ 903.08 crore. This represent the growth of 3.26% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 424.65 crore over 8 quarters. This represents a CAGR of -7.30% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Mankind Pharma Ltd News Hub

News

Mankind Pharma allots 57,709 equity shares under ESOP

Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Comp...

Read more

10 Jun 2025 13:26

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

23 May 2025 13:35

News

Mankind Pharma slides after Q4 PAT drops 11% YoY to Rs 421 cr

However, revenue from operations increased 27.19% year-on-year (YoY) to Rs 3,079.37 crore ...

Read more

22 May 2025 15:37

News

Board of Mankind Pharma approves incorporation of WoS in Sri Lanka

The Board of Mankind Pharma at its meeting held on 21 May 2025 has approved the incorporat...

Read more

21 May 2025 18:52

News

Mankind Pharma allots 92,512 equity shares under ESOP

Mankind Pharma has allotted 92,512 equity shares under ESOP on 21 May 2025. Consequent to ...

Read more

21 May 2025 14:16

News

Mankind Pharma to discuss results

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2025...

Read more

09 May 2025 10:55

Natco Pharma Ltd News Hub

News

Natco Pharma Ltd gains for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908...

Read more

11 Jun 2025 13:05

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Mankind Pharma Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Mankind Pharma Ltd or Natco Pharma Ltd?

Market cap of Mankind Pharma Ltd is 98,498 Cr while Market cap of Natco Pharma Ltd is 16,552 Cr

What are the key factors driving the stock performance of Mankind Pharma Ltd and Natco Pharma Ltd?

The stock performance of Mankind Pharma Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mankind Pharma Ltd and Natco Pharma Ltd?

As of June 13, 2025, the Mankind Pharma Ltd stock price is INR ₹2386.85. On the other hand, Natco Pharma Ltd stock price is INR ₹924.15.

How do dividend payouts of Mankind Pharma Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Mankind Pharma Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions